Augustine Asset Management Inc. Cuts Stock Position in Sanofi (NASDAQ:SNY)

Augustine Asset Management Inc. decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 2.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,075 shares of the company’s stock after selling 1,913 shares during the quarter. Sanofi comprises approximately 1.0% of Augustine Asset Management Inc.’s holdings, making the stock its 19th biggest holding. Augustine Asset Management Inc.’s holdings in Sanofi were worth $3,910,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in SNY. AQR Capital Management LLC purchased a new stake in shares of Sanofi during the second quarter valued at approximately $344,000. UMB Bank n.a. grew its holdings in Sanofi by 39.2% during the 3rd quarter. UMB Bank n.a. now owns 1,073 shares of the company’s stock valued at $62,000 after purchasing an additional 302 shares in the last quarter. Koshinski Asset Management Inc. purchased a new stake in Sanofi during the 3rd quarter worth $211,000. Grove Bank & Trust boosted its position in Sanofi by 5.6% in the 3rd quarter. Grove Bank & Trust now owns 5,691 shares of the company’s stock valued at $328,000 after buying an additional 300 shares during the last quarter. Finally, Creative Planning boosted its position in Sanofi by 18.0% in the 3rd quarter. Creative Planning now owns 220,763 shares of the company’s stock valued at $12,723,000 after buying an additional 33,728 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY stock opened at $53.90 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. The stock has a market capitalization of $136.79 billion, a price-to-earnings ratio of 21.65, a PEG ratio of 0.99 and a beta of 0.57. Sanofi has a one year low of $45.22 and a one year high of $58.97. The company’s 50-day simple moving average is $49.94 and its 200-day simple moving average is $52.40.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. Equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several recent analyst reports. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.